56.66
price down icon1.46%   -0.84
after-market Handel nachbörslich: 56.62 -0.04 -0.07%
loading

Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten

pulisher
Oct 13, 2025

Why Scholar Rock Stock Got Socked on Monday - The Motley Fool

Oct 13, 2025
pulisher
Oct 11, 2025

Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm

Oct 11, 2025
pulisher
Oct 11, 2025

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 10, 2025

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Oct 10, 2025
pulisher
Oct 09, 2025

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm

Oct 09, 2025
pulisher
Oct 02, 2025

BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail

Oct 02, 2025
pulisher
Oct 01, 2025

J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 01, 2025
pulisher
Sep 28, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa

Sep 28, 2025
pulisher
Sep 27, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India

Sep 27, 2025
pulisher
Sep 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent

Sep 24, 2025
pulisher
Sep 24, 2025

NVO Stock Quote Price and Forecast - CNN

Sep 24, 2025
pulisher
Sep 23, 2025

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 23, 2025
pulisher
Sep 20, 2025

NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 20, 2025
pulisher
Sep 19, 2025

Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com

Sep 19, 2025
pulisher
Sep 18, 2025

Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize

Sep 18, 2025
pulisher
Sep 18, 2025

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm

Sep 18, 2025
pulisher
Sep 18, 2025

Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study - Sahm

Sep 18, 2025
pulisher
Sep 17, 2025

How Do Investors Really Feel About Novo Nordisk? - Sahm

Sep 17, 2025
pulisher
Sep 17, 2025

NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 17, 2025
pulisher
Sep 17, 2025

Live market analysis of Novo Nordisk A s (b Shares) AdrhedgedInsider Buying & Comprehensive Market Scan Insights - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Published on: 2025-09-17 04:52:55 - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Advanced analytics toolkit walkthrough for Novo Nordisk A s (b Shares) AdrhedgedGap Down & AI Powered Trade Plan Recommendations - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - Sahm

Sep 17, 2025
drug_manufacturers_general MRK
$84.70
price down icon 1.17%
$293.85
price up icon 0.49%
$118.48
price up icon 0.23%
drug_manufacturers_general PFE
$24.52
price down icon 0.85%
drug_manufacturers_general SNY
$49.22
price up icon 0.86%
Kapitalisierung:     |  Volumen (24h):